Hengrui Announces Drug Inclusions in China’s 2026 NRDLTip Ranks·Nov 15, 2026 at 11:07 AM01276-2.27%600276-1.59%
Weekly Recap | HENGRUI PHARMA -3.2%, most brokers rate it buy or overweightWeekly Review·Nov 14, 2026 at 05:05 AM01276-2.27%
Weekly Recap | HENGRUI PHARMA +3.67%, consensus target above spotWeekly Review·Nov 7, 2026 at 09:34 AM01276-2.27%
Hengrui Pharma and Braveheart Bio Present Data from 52-Week Open-Label Extension of Phase 2 Study of HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at American Heart Association Scientific Sessions 2026 | BRVE Stock NewsStockTitan·Nov 6, 2026 at 12:15 PMBRVE-3.64%01276-2.27%
Jiangsu Hengrui Appoints Zhang Wei as Senior Vice PresidentPUBT·Nov 3, 2026 at 09:04 AM01276-2.27%600276-1.59%
Citi: China Pharma and Biotech ESMO Data Further Validated; Favors CSPC PHARMA , HENGRUI PHARMA , INNOVENT BIO and SKB BIOAASTOCKS News·Nov 2, 2026 at 10:30 AM01093+1.20%01276-2.27%
Hengrui presenta investigaciones innovadoras en el Congreso ESMO 2026prnewswire·Oct 29, 2026 at 07:13 AM01276-2.27%600276-1.59%
China’s Hengrui Pharma Soars Amid Strong Earnings Growth in First Nine Months Driven by Innovative Drug BusinessYicai·Oct 28, 2026 at 07:01 AM01276-2.27%600276-1.59%
From China to the Global Stage: Hengrui Showcases Innovative Research at ESMO Congress 2026, Exploring New Approaches to Oncology Treatmentprnewswire·Oct 28, 2026 at 03:33 AM01276-2.27%600276-1.59%
Hengrui Medicine surges 10% as Q3 profit jumps 89%HK Stock Market Update·Oct 28, 2026 at 01:35 AM01276-2.27%
Hengrui Pharma surges 11% as Q3 profit beats estimatesMarket Movers·Oct 28, 2026 at 01:32 AM01276-2.27%
China’s Hengrui posts 89% rise in third-quarter net profit, beating estimatesSCMP·Oct 28, 2026 at 12:02 AM01276-2.27%600276-1.59%
Hengrui Pharma Q3 2026 net profit attributable to shareholders jumps 89% to RMB 2.46 billionPUBT·Oct 27, 2026 at 12:13 PM01276-2.27%600276-1.59%
Chinese Drug Licensing Boom Seen Intact as Proposed US Curbs Cloud Equity DealsYicai·Oct 27, 2026 at 10:54 AM01276-2.27%01530-4.04%